Novel CDNF/MANF family of neurotrophic factors

Developmental Neurobiology

Volumn 70, Issue 5, 2010, Pages 360-371

  Lindholm, Päivi ^a   Saarma, Mart ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Dopamine neurons; Lipids; Neurotrophic factors; Parkinson's disease; Receptors; Saposins

Indexed keywords

CEREBRAL DOPAMINE NEUROTROPHIC FACTOR; CYSTEINE; DOPAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LIPID; MESENCEPHALIC ASTROCYTE DERIVED NEUROTROPHIC FACTOR; NEUROTROPHIC FACTOR; OXIDOPAMINE; SPHINGOLIPID ACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ASTROCYTE; BRAIN NERVE CELL; CAENORHABDITIS; CARBOXY TERMINAL SEQUENCE; CELL MEMBRANE; CLINICAL TRIAL; CRYSTAL STRUCTURE; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; DROSOPHILA; ENDOPLASMIC RETICULUM STRESS; FLY; HUMAN; INVERTEBRATE; MOLECULAR MECHANICS; MOTOR PERFORMANCE; NEURITE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW;

ANIMALS; DOPAMINE; ENDOPLASMIC RETICULUM; HUMANS; MODELS, NEUROLOGICAL; NERVE GROWTH FACTORS; NEURONS; STRESS, PHYSIOLOGICAL;

EID: 77949691167     PISSN: 19328451     EISSN: 10974695     Source Type: Journal    
DOI: 10.1002/dneu.20760     Document Type: Review

References (82)

1. Ahn VE, Faull KF, Whitelegge JP, Fluharty AL, Prive GG. 2003. Crystal structure of saposin B reveals a dimeric shell for lipid binding. Proc Natl Acad Sci USA 100:38-43.
2. Ahn VE, Leyko P, Alattia JR, Chen L, Prive GG. 2006. Crystal structures of saposins A and C. Protein Sci 15:1849-1857.
3. Airaksinen MS, Holm L, Hätinen T. 2006. Evolution of the GDNF family ligands and receptors. Brain Behav Evol 68:181-190.
4. Airaksinen MS, Saarma M. 2002. The GDNF family: Signalling, biological functions and therapeutic value. Nat Rev Neurosci 3:383-394.
5. Airavaara M, Shen H, Kuo CC, Peränen J, Saarma M, Hoffer B, Wang Y. 2009. Mesencephalic astrocyte-derived neurotrophic factor reduces ischemic brain injury and promotes behavioral recovery in rats. J Comp Neurol 515:116-124.
6. Anderson DH, Sawaya MR, Cascio D, Ernst W, Modlin R, Krensky A, Eisenberg D. 2003. Granulysin crystal structure and a structure-derived lytic mechanism. J Mol Biol 325:355-365.
7. Andersson M, Gunne H, Agerberth B, Boman A, Bergman T, Sillard R, Jornvall H, et al. 1995. NK-lysin, a novel effector peptide of cytotoxic T and NK cells. Structure and cDNA cloning of the porcine form, induction by interleukin 2, antibacterial and antitumour activity. EMBO J 14:1615-1625.
8. Andressoo JO, Saarma M. 2008. Signalling mechanisms underlying development and maintenance of dopamine neurons. Curr Opin Neurobiol 18:297-306.
9. Apostolou A, Shen Y, Liang Y, Luo J, Fang S. 2008. Armet, a UPR-upregulated protein, inhibits cell proliferation and ER stress-induced cell death. Exp Cell Res 314:2454-2467.
10. Bauer S, Kerr BJ, Patterson PH. 2007. The neuropoietic cytokine family in development, plasticity, disease and injury. Nat Rev Neurosci 8:221-232.
11. Belmont PJ, Tadimalla A, Chen WJ, Martindale JJ, Thuerauf DJ, Marcinko M, Gude N, et al. 2008. Coordination of growth and endoplasmic reticulum stress signaling by regulator of calcineurin 1 (RCAN1), a novel ATF6-inducible gene. J Biol Chem 283:14012-14021.
12. Bespalov MM, Saarma M. 2007. GDNF family receptor complexes are emerging drug targets. Trends Pharmacol Sci 28:68-74.
13. Bruhn H. 2005. A short guided tour through functional and structural features of saposin-like proteins. Biochem J 389:249-257.
14. Burke RE. 2004. Ontogenic cell death in the nigrostriatal system. Cell Tissue Res 318:63-72.
15. Chauhan NB, Siegel GJ, Lee JM. 2001. Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain. J Chem Neuroanat 21:277-288.
16. Ellgaard L, Ruddock LW. 2005. The human protein disulphide isomerase family: Substrate interactions and functional properties. EMBO Rep 6:28-32.
17. Evron E, Cairns P, Halachmi N, Ahrendt SA, Reed AL, Sidransky D. 1997. Normal polymorphism in the incomplete trinucleotide repeat of the arginine-rich protein gene. Cancer Res 57:2888-2889.
18. Fontan A, Rojo A, Sanchez Pernaute R, Hernandez I, Lopez I, Castilla C, Sanchez Albisua J, et al. 2002. Effects of fibroblast growth factor and glial-derived neurotrophic factor on akinesia, F-DOPA uptake and dopamine cells in parkinsonian primates. Parkinsonism Relat Disord 8:311-323.
19. Gill SS, Patel NK, Hotton GR, O'sullivan K, McCarter R, Bunnage M, Brooks DJ, et al. 2003. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9:589-595.
20. Grothe C, Timmer M. 2007. The physiological and pharmacological role of basic fibroblast growth factor in the dopaminergic nigrostriatal system. Brain Res Rev 54:80-91.
21. Harpster MH, Bandyopadhyay S, Thomas DP, Ivanov PS, Keele JA, Pineguina N, Gao B, et al. 2006. Earliest changes in the left ventricular transcriptome postmyocardial infarction. Mamm Genome 17:701-715.
22. Hawkins CA, de Alba E, Tjandra N. 2005. Solution structure of human saposin C in a detergent environment. J Mol Biol 346:1381-1392.
23. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. 2003. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374:1-20.
24. Hoffer BJ, Hoffman A, Bowenkamp K, Huettl P, Hudson J, Martin D, Lin LF, et al. 1994. Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci Lett 182:107-111.
25. Hogg PJ. 2003. Disulfide bonds as switches for protein function. Trends Biochem Sci 28:210-214.
26. Holtz WA, Turetzky JM, O'Malley KL. 2005. Microarray expression profiling identifies early signaling transcripts associated with 6-OHDA-induced dopaminergic cell death. Antioxid Redox Signal 7:639-648.
27. Hovland DN Jr, Boyd RB, Butt MT, Engelhardt JA, Moxness MS, Ma MH, Emery MG, et al. 2007. Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF) in rhesus monkeys. Toxicol Pathol 35:676-692.
28. Howells DW, Porritt MJ, Wong JY, Batchelor PE, Kalnins R, Hughes AJ, Donnan GA. 2000. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. Exp Neurol 166:127-135.
29. Huang EJ, Reichardt LF. 2001. Neurotrophins: Roles in neuronal development and function. Annu Rev Neurosci 24:677-736.
30. Hudson J, Granholm AC, Gerhardt GA, Henry MA, Hoffman A, Biddle P, Leela NS, et al. 1995. Glial cell line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivo. Brain Res Bull 36:425-432.
31. Jongstra J, Schall TJ, Dyer BJ, Clayberger C, Jorgensen J, Davis MM, Krensky AM. 1987. The isolation and sequence of a novel gene from a human functional T cell line. J Exp Med 165:601-614.
32. Jordan PA, Gibbins JM. 2006. Extracellular disulfide exchange and the regulation of cellular function. Antioxid Redox Signal 8:312-324.
33. Jørgensen JR, Thompson L, Fjord-Larsen L, Krabbe C, Torp M, Kalkkinen N, Hansen C, et al. 2009. Characterization of meteorin - An evolutionary conserved neurotrophic factor. J Mol Neurosci 39:104-116.
34. Kadota T, Shingo T, Yasuhara T, Tajiri N, Kondo A, Morimoto T, Yuan WJ, et al. 2009. Continuous intraventricular infusion of erythropoietin exerts neuroprotective/rescue effects upon Parkinson's disease model of rats with enhanced neurogenesis. Brain Res 1254:120-127.
35. Kotani Y, Matsuda S, Sakanaka M, Kondoh K, Ueno S, Sano A. 1996. Prosaposin facilitates sciatic nerve regeneration in vivo. J Neurochem 66:2019-2025.
36. Krieglstein K. 2004. Factors promoting survival of mesencephalic dopaminergic neurons. Cell Tissue Res 318:73-80.
37. Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R, Brooks DJ, et al. 2006. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 59:459-466.
38. Lee AH, Iwakoshi NN, Glimcher LH. 2003. XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response. Mol Cell Biol 23:7448-7459.
39. Levi-Montalcini R. 1987. The nerve growth factor 35 years later. Science 237:1154-1162.
40. Liepinsh E, Andersson M, Ruysschaert JM, Otting G. 1997. Saposin fold revealed by the NMR structure of NK-lysin. Nat Struct Biol 4:793-795.
41. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. 1993. GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260:1130-1132.
42. Lindholm P, Peränen J, Andressoo JO, Kalkkinen N, Kokaia Z, Lindvall O, Timmusk T, et al. 2008. MANF is widely expressed in mammalian tissues and differently regulated after ischemic and epileptic insults in rodent brain. Mol Cell Neurosci 39:356-371.
43. Lindholm P, Voutilainen MH, Laurén J, Peränen J, Leppänen VM, Andressoo JO, Lindahl M, et al. 2007. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature 448:73-77.
44. Liu J, Wang CY, O'Brien JS. 2001. Prosaptide D5, a retroinverso 11-mer peptidomimetic, rescued dopaminergic neurons in a model of Parkinson's disease. FASEB J 15:1080-1082.
45. Love S, Plaha P, Patel NK, Hotton GR, Brooks DJ, Gill SS. 2005. Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat Med 11:703-704.
46. Lu B, Pang PT, Woo NH. 2005. The yin and yang of neurotrophin action. Nat Rev Neurosci 6:603-614.
47. Mizobuchi N, Hoseki J, Kubota H, Toyokuni S, Nozaki J, Naitoh M, Koizumi A, et al. 2007. ARMET is a soluble ER protein induced by the unfolded protein response via ERSE-II element. Cell Struct Funct 32:41-50.
48. Mogi M, Togari A, Kondo T, Mizuno Y, Komure O, Kuno S, Ichinose H, et al. 1999. Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neurosci Lett 270:45-48.
49. Nishino J, Yamashita K, Hashiguchi H, Fujii H, Shimazaki T, Hamada H. 2004. Meteorin: A secreted protein that regulates glial cell differentiation and promotes axonal extension. EMBO J 23:1998-2008.
50. O'Brien JS, Carson GS, Seo HC, Hiraiwa M, Kishimoto Y. 1994. Identification of prosaposin as a neurotrophic factor. Proc Natl Acad Sci USA 91:9593-9596.
51. O'Brien JS, Carson GS, Seo HC, Hiraiwa M, Weiler S, Tomich JM, Barranger JA, et al. 1995. Identification of the neurotrophic factor sequence of prosaposin. FASEB J 9:681-685.
52. Palgi M, Lindström R, Peränen J, Piepponen TP, Saarma M, Heino TI. 2009. Evidence that DmMANF is an invertebrate neurotrophic factor supporting dopaminergic neurons. Proc Natl Acad Sci USA 106:2429-2434.
53. Parain K, Murer MG, Yan Q, Faucheux B, Agid Y, Hirsch E, Raisman-Vozari R. 1999. Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra. Neuroreport 10:557-561.
54. Parkash V, Lindholm P, Peränen J, Kalkkinen N, Oksanen E, Saarma M, Leppänen VM, et al. 2009. The structure of the conserved neurotrophic factors MANF and CDNF explains why they are bifunctional. Protein Eng Des Sel 22:233-241.
55. Patel NK, Bunnage M, Plaha P, Svendsen CN, Heywood P, Gill SS. 2005. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: A two-year outcome study. Ann Neurol 57:298-302.
56. Pena SV, Hanson DA, Carr BA, Goralski TJ, Krensky AM. 1997. Processing, subcellular localization, and function of 519 (granulysin), a human late T cell activation molecule with homology to small, lytic, granule proteins. J Immunol 158:2680-2688.
57. Petrova P, Raibekas A, Pevsner J, Vigo N, Anafi M, Moore MK, Peaire AE, et al. 2003. MANF: A new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons. J Mol Neurosci 20:173-188.
58. Piepoli A, Gentile A, Valvano MR, Barana D, Oliani C, Cotugno R, Quitadamo M, et al. 2006. Lack of association between UGT1A7. UGT1A9, ARP, SPINK1 and CFTR gene polymorphisms and pancreatic cancer in Italian patients. World J Gastroenterol 12:6343-6348.
59. Puskovic V, Wolfe D, Wechuck J, Krisky D, Collins J, Glorioso JC, Fink DJ, et al. 2006. HSV-mediated delivery of erythropoietin restores dopaminergic function in MPTP-treated mice. Mol Ther 14:710-715.
60. Raykhel I, Alanen H, Salo K, Jurvansuu J, Nguyen VD, Latva-Ranta M, Ruddock L. 2007. A molecular specificity code for the three mammalian KDEL receptors. J Cell Biol 179:1193-1204.
61. Romero-Ramirez L, Cao H, Nelson D, Hammond E, Lee AH, Yoshida H, Mori K, et al. 2004. XBP1 is essential for survival under hypoxic conditions and is required for tumor growth. Cancer Res 64:5943-5947.
62. Rossmann M, Schultz-Heienbrok R, Behlke J, Remmel N, Alings C, Sandhoff K, Saenger W, et al. 2008. Crystal structures of human saposins C and D: Implications for lipid recognition and membrane interactions. Structure 16:809-817.
63. Sauer H, Oertel WH. 1994. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59:401-415.
64. Schober A. 2004. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res 318:215-224.
65. Schwertassek U, Balmer Y, Gutscher M, Weingarten L, Preuss M, Engelhard J, Winkler M, et al. 2007. Selective redox regulation of cytokine receptor signaling by extracellular thioredoxin-1. EMBO J 26:3086-3097.
66. Shridhar R, Shridhar V, Rivard S, Siegfried JM, Pietraszkiewicz H, Ensley J, Pauley R, et al. 1996a. Mutations in the arginine-rich protein gene, in lung, breast, and prostate cancers, and in squamous cell carcinoma of the head and neck. Cancer Res 56:5576-5578.
67. Shridhar V, Rivard S, Shridhar R, Mullins C, Bostick L, Sakr W, Grignon D, et al. 1996b. A gene from human chromosomal band 3p21.1 encodes a highly conserved arginine-rich protein and is mutated in renal cell carcinomas. Oncogene 12:1931-1939.
68. Shridhar V, Rivard S, Wang X, Shridhar R, Paisley C, Mullins C, Beirnat L, et al. 1997. Mutations in the arginine-rich protein gene (ARP) in pancreatic cancer. Oncogene 14:2213-2216.
69. Silva RM, Ries V, Oo TF, Yarygina O, Jackson-Lewis V, Ryu EJ, Lu PD, et al. 2005. CHOP/GADD153 is a mediator of apoptotic death in substantia nigra dopamine neurons in an in vivo neurotoxin model of parkinsonism. J Neurochem 95:974-986.
70. Slevin JT, Gerhardt GA, Smith CD, Gash DM, Kryscio R, Young B. 2005. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg 102:216-222.
71. Sugaya R, Ishimaru S, Hosoya T, Saigo K, Emori Y. 1994. A Drosophila homolog of human proto-oncogene ret transiently expressed in embryonic neuronal precursor cells including neuroblasts and CNS cells. Mech Dev 45:139-145.
72. Szegezdi E, Duffy A, O'Mahoney ME, Logue SE, Mylotte LA, O'Brien T, Samali A. 2006a. ER stress contributes to ischemia-induced cardiomyocyte apoptosis. Biochem Biophys Res Commun 349:1406-1411.
73. Szegezdi E, Logue SE, Gorman AM, Samali A. 2006b. Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Rep 7:880-885.
74. Tadimalla A, Belmont PJ, Thuerauf DJ, Glassy MS, Martindale JJ, Gude N, Sussman MA, et al. 2008. Mesencephalic astrocyte-derived neurotrophic factor is an ischemia-inducible secreted endoplasmic reticulum stress response protein in the heart. Circ Res 103:1249-1258.
75. Tanaka H, Shimada Y, Harada H, Shinoda M, Hatooka S, Imamura M, Ishizaki K. 2000. Polymorphic variation of the ARP gene on 3p21 in Japanese esophageal cancer patients. Oncol Rep 7:591-593.
76. Uehara T, Nakamura T, Yao D, Shi ZQ, Gu Z, Ma Y, Masliah E, et al. 2006. S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration. Nature 441:513-517.
77. Vaccaro AM, Salvioli R, Barca A, Tatti M, Ciaffoni F, Maras B, Siciliano R, et al. 1995. Structural analysis of saposin C and B. Complete localization of disulfide bridges. J Biol Chem 270:9953-9960.
78. Vogel A, Schwarzmann G, Sandhoff K. 1991. Glycosphingolipid specificity of the human sulfatide activator protein. Eur J Biochem 200:591-597.
79. Voutilainen MH, Bäck S, Pörsti E, Toppinen L, Lindgren L, Lindholm P, Peränen J, et al. 2009. Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson's disease. J Neurosci 29:9651-9659.
80. Yasuhara T, Shingo T, Muraoka K, Kameda M, Agari T, Wen Ji Y, Hayase H, et al. 2005. Neurorescue effects of VEGF on a rat model of Parkinson's disease. Brain Res 1053:10-18.
81. Zacchigna S, Lambrechts D, Carmeliet P. 2008. Neurovascular signalling defects in neurodegeneration. Nat Rev Neurosci 9:169-181.
82. Zhu B, Pennack JA, McQuilton P, Forero MG, Mizuguchi K, Sutcliffe B, Gu CJ, et al. 2008. Drosophila neurotrophins reveal a common mechanism for nervous system formation. PLoS Biol 6:e284.